Eli Lilly Jumped 6% After Earnings. It's Up 68% in a Year.

Impact · against what's priced in

Eli Lilly's upward guidance and pipeline milestones act as catalysts because the current price was explicitly betting against sustained growth above 30% and ignoring the next-gen pipeline. While price erosion in Tirzepatide is a headwind, the magnitude of the revenue beat and the Retatrutide timeline shift the risk-reward profile higher.

LLY+0.50: Challenges what's priced in
The price assumes: Sustaining growth above 30% beyond 2026

Eli Lilly Jumped 6% After Earnings. It's Up 68% in a Year.

What matters in this story

Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?

Eli Lilly Jumped 6% After Earnings. It's Up 68% in a Year.

What matters in this story

Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?

How each ticker is affected

Connected tickers

Track these names every morning.

Novo Before Q3 Earnings: How Should Investors Play the Stock?

Can CAH's Specialty Strength Offset Medical Distribution Challenges in Q1?

Diversify Your Income By Hiring Specialists

JKHY Set to Report Q1 Earnings: What's in Store for the Stock?

Eli Lilly Jumped 6% After Earnings. It's Up 68% in a Year.

What matters in this story

Next reads from the same story arc

Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?

Eli Lilly Jumped 6% After Earnings. It's Up 68% in a Year.

What matters in this story

Next reads from the same story arc

Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?

How each ticker is affected

Connected tickers

Track these names every morning.

Novo Before Q3 Earnings: How Should Investors Play the Stock?

Can CAH's Specialty Strength Offset Medical Distribution Challenges in Q1?

Diversify Your Income By Hiring Specialists

JKHY Set to Report Q1 Earnings: What's in Store for the Stock?